Posts

China Approves Lilly and Innovent's Mazdutide, Marking New Era for GLP-1 Obesity Drugs

on

Alphabet's Calico Strikes $596M Deal for Mabwell's Anti-Aging Antibody

on

RFK Jr.'s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy

on

Novavax Approval Process Raises Concerns Among Former Regulators About FDA Integrity

on

Trump's CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment

on

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

on

Altimmune's Incretin Misses Fibrosis Improvement Endpoints in MASH Trial

on

ACIP Backs Merck's Enflonsia for RSV Prevention in Infants

on

Vor Bio's $4B+ Revival Deal for RemeGen's Autoimmune Drug Triggers Divergent Stock Moves

on

Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact

on

Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines

on

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

on

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

on

Bayer's BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move

on

Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal

on

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

on

FDA Investigates Patient Deaths Linked to Sarepta's Elevidys Gene Therapy for Duchenne Muscular Dystrophy

on

Kymera Faces Sanofi Setback but Secures $750M Gilead Oncology Deal

on

Leap Therapeutics Slashes 75% of Workforce, Ends Clinical Trial, Considers Strategic Options

on

Nektar Declares Phase IIb Eczema Win for Rezpeg, but Analysts Remain Skeptical

on

Nuvalent Reports Positive Pivotal Data for ROS1-Targeted Lung Cancer Drug; Rolling FDA Submission Planned

on

BrightGene's Dual GLP-1/GIP Agonist BGM0504 Shows Promise in Phase 2 Diabetes and Obesity Trials at ADA25

on

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

on

Hims & Hers Stock Plunges 30% as Novo Nordisk Ends Wegovy Sales Deal

on

FDA Acting CDER Head Jacqueline Corrigan-Curay to Retire Amid Leadership Turnover

on

Sen. Bill Cassidy Calls for Deferral of CDC Vaccine Meeting After RFK Jr. Panel Shakeup

on

BrightGene's BGM0504 Outperforms Novo Nordisk's Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

on

Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development

on

Sanofi Licenses Formation Bio's JAK/SYK Inhibitor Gusacitinib in $630M+ AI-Driven Deal

on

Illumina Acquires SomaLogic to Accelerate Proteomics Strategy with $350M Upfront

on

Exelixis' Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

on

Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles

on

Exelixis' Phase 3 Colorectal Cancer Data Sends Stock Higher

on

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

on

Vertex's Islet Cell Therapy Shows Dramatic Reduction in Dangerous Low Blood Sugar Levels in Type 1 Diabetes Trial

on

FDA's Top Cell and Gene Therapy Leaders Exit Amid CBER Upheaval

on

CHMP Recommends Five New Drugs and Reviews Eli Lilly's Kisunla

on

Inside the FDA’s Listening Tour: Officials Agree US Lags Behind China on Drug Development

on

Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot

on

Zealand Pharma's Dual GLP-1/GLP-2 Agonist Dapiglutide Shows Promising 11.6% Weight Loss at 28 Weeks

on

Recent Developments in Immune Profiling for Early Immuno-Oncology Trials

on

FDA Grants Dupixent (Dupilumab) Eighth Approval: Now Cleared for Bullous Pemphigoid

on

Trump Administration Considers Limits on Direct-to-Consumer Drug Advertising

on